Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Modular Medical, Inc.MODD · Entity 7488 | Director | September 30, 2026 | October 02, 2026 |
| OptimizeRx CorpOPRX · Entity 213 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Modular Medical, Inc.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2036-09-30 | Direct | 250 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 250 · Balance 250 F1: The option was granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the option was fully vested and exercisable on the grant date. F2: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in Column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class." |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the option was fully vested and exercisable on the grant date.
F2: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in Column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class."
OptimizeRx Corp
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,159 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 34,517 · Balance 107,159 F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aspira Women's Health Inc.
Report date June 04, 2025 · Filed June 06, 2025
Section 16 reporting ended · disclosed 2025-06-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,989 |
Reported balance
After 2025-06-04 transaction · row 1
1 source rowRow 1 · 2025-06-04 · Exercise / conversion · Acquired 5,312 · Balance 73,989 F1: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 21,250 RSUs, 5,312 of which vested on June 4, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-04 · Exercise / conversion · Disposed 5,312 · Balance 0 F2: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F3: On August 22, 2024, the reporting person was granted 21,250 RSUs, 5,312 of which vested on June 4, 2025. The common stock into which such vested RSUs converted on June 4, 2025 is reported in Table I on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 21,250 RSUs, 5,312 of which vested on June 4, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.
F2: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.
F3: On August 22, 2024, the reporting person was granted 21,250 RSUs, 5,312 of which vested on June 4, 2025. The common stock into which such vested RSUs converted on June 4, 2025 is reported in Table I on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2021 Filed Nov 1, 2021 23:52 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock | 55,555 | $2.70 | $149,998.50 |
DisclosureSEC source: 0001019056-21-000555 · vos.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,562 F1 · security: On October 28, 2021, the reporting person entered into a common stock purchase agreement with the Issuer and purchased 55,555 shares of the Company's common stock, par value $0.001 per share, at the closing market price on October 28, 2021 of $2.70 per share. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-051139 · ownership.xml · derivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334 Underlying: Common Stock · 334 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on September 29, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| August 11, 2021 Filed Aug 16, 2021 18:46 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantOption to purchase common stock · Derivative | 1,087,354 | $4.06 Strike: $4.06 | $4,414,657.24 |
DisclosureSEC source: 0001019056-21-000477 · vos.xml · derivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,087,354 Underlying: Common Stock · 1,087,354 shares Expires 2031-08-11 F1 · security: Twenty percent of the shares subject to the option vest after six months with the remaining shares subject to the option vesting in equal monthly amounts over the next 42 months. F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in Column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class." As a result of the grant reported herein, the Reporting Person currently has aggregate options to purchase a total of 1,143,361 shares of the Issuer. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 20:49 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 407 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-035082 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,890 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 19:40 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantOption to purchase common stock · Derivative | 6,007 | $5.90 Strike: $5.90 | $35,441.30 |
DisclosureSEC source: 0001019056-21-000407 · vos.xml · derivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,007 Underlying: Common Stock · 6,007 shares Expires 2031-06-30 F1 · security: The option was granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the option was fully vested and exercisable on the grant date. F2 · balance_after: In accordance with Instruction 4 to this Form, column 9 reports only total beneficial ownership of the "class" of derivative security reported in Column 1. Options that have different exercise prices or vesting terms are not considered to be of the same "class." As a result of the grant reported herein, the Reporting Person currently has aggregate options to purchase a total of 56,007 shares of the Issuer. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:01 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantOption to purchase common stock · Derivative | 50,000 | $4.95 Strike: $4.95 | $247,500.00 |
DisclosureSEC source: 0001019056-21-000316 · vos.xml · derivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-05-18 F1 · security: This option will vest as to one-third of the shares subject to the option on each annual anniversary of May 18, 2021. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:42 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 539 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-019882 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,483 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:46 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 802 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-000457 · ownership.xml · nonDerivative · entry 2 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,944 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 21:46 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 1,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-000457 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,142 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:36 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 1,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-016585 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 16:10 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $8.75 | $8,750.00 |
DisclosureSEC source: 0001213900-20-008316 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,022 Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 12:46 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008138 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,022 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 21:31 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-000385 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,238 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 16:23 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 600 | $9.62 | $5,772.00 |
DisclosureSEC source: 0001213900-19-023370 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,154 Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:18 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-019545 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,554 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 20:23 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005248 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,386 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 21:20 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-013770 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,302 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 18:43 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-008681 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,218 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:03 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 250 | $10.72 | $2,680.00 |
DisclosureSEC source: 0001213900-18-008317 · ownership.xml · nonDerivative · entry 4 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,134 Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:03 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,100 | $10.47 | $11,517.00 |
DisclosureSEC source: 0001213900-18-008317 · ownership.xml · nonDerivative · entry 3 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,884 Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 16:03 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 50 | $10.29 | $514.50 |
DisclosureSEC source: 0001213900-18-008317 · ownership.xml · nonDerivative · entry 2 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,784 Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 16:03 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 400 | $10.35 | $4,140.00 |
DisclosureSEC source: 0001213900-18-008317 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,734 Read SEC document |
| May 03, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.75 | $750.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 22 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 28,000 Read SEC document |
| April 12, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,000 | $0.74 | $1,480.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 21 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 27,000 Read SEC document |
| March 24, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.81 | $810.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 20 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 25,000 Read SEC document |
| March 23, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.81 | $810.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 19 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 24,000 Read SEC document |
| March 22, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,000 | $0.81 | $1,620.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 18 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 23,000 Read SEC document |
| March 21, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.80 | $800.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 17 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 21,000 Read SEC document |
| March 20, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.81 | $810.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 16 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 20,000 Read SEC document |
| March 17, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.81 | $810.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 15 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 19,000 Read SEC document |
| March 16, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,000 | $0.82 | $1,640.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 14 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,000 Read SEC document |
| March 14, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.85 | $850.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 13 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 16,000 Read SEC document |
| March 13, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,000 | $0.81 | $1,620.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 12 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 15,000 Read SEC document |
| March 10, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.81 | $810.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 11 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 13,000 Read SEC document |
| March 06, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.85 | $850.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 10 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,000 Read SEC document |
| March 01, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.70 | $700.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 9 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 11,000 Read SEC document |
| February 28, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.71 | $710.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 8 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 10,000 Read SEC document |
| February 21, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.75 | $750.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 7 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 9,000 Read SEC document |
| February 15, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.77 | $770.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 6 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 8,000 Read SEC document |
| February 10, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,000 | $0.70 | $1,400.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 5 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 7,000 Read SEC document |
| February 09, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,000 | $0.75 | $1,500.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 4 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 5,000 Read SEC document |
| February 08, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.73 | $730.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 3 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,000 Read SEC document |
| February 08, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.76 | $760.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 2 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,000 Read SEC document |
| February 06, 2017 Filed May 31, 2017 20:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $0.77 | $770.00 |
DisclosureSEC source: 0001213900-17-006023 · f4020617vos_optimizerx.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.